Goal-directed Afterload Reduction in Acute Congestive Cardiac Decompensation Study

Acute Heart Failure Clinical Trial

— GALACTIC  

Official title:

Goal-Directed Afterload Reduction in Acute Congestive Cardiac Decompensation Study (GALACTIC)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00512759
• Other study ID #: GALACTIC
• Status: Completed
• Phase: Phase 4
• Start date: December 10, 2007
• Est. completion date: February 21, 2019

Study information

• Verified date: November 2019
• Source: University Hospital, Basel, Switzerland
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to determine whether an early goal-directed decrement of preload and afterload with a target systolic blood pressure of 90-110 mmHg by aggressive vasodilatation in patients with acute HF in the non-ICU setting is safe, and leads to a better clinical and economical outcome

Description:

Background: Heart failure (HF) is a chronic and progressive illness resulting from a variety of cardiac causes, including ischemic and valvular heart disease, dilatative cardiomyopathy or hypertension. HF may also develop suddenly, particularly as a complication of acute myocardial infarction or as an acute exacerbation in patients with previously compensated chronic HF. Acute HF requires immediate treatment that centers on reducing myocardial oxygen demand and augmenting forward blood flow by removal of excess fluid with diuretics and reduction of preload and afterload with vasodilatators. The aging of our population and the higher number of patients surviving acute myocardial infarctions have lead to a dramatic increase in the incidence and prevalence of HF, and obviously also on total cost burden of the disease. For multiple reasons including need for restrictive use of the limited number of ICU hospital beds the vast majority of elderly patients with acute HF are treated in a non-ICU setting. Unfortunately, the optimal treatment of acute HF in the non-ICU setting is not well defined. Pathophysiological considerations and preliminary data from the ICU setting suggest that aggressive venous and arterial vasodilation may improve short and long-term outcome.

Aim: To test the hypotheses that:

• An early goal-directed decrement of preload and afterload with a target systolic blood pressure of 90-110 mmHg by aggressive vasodilatation in patients with acute HF in the non-ICU setting is safe, and leads to a better clinical and economical outcome

Methods:

Design: Prospective, randomized, controlled, open label, interventional study Setting:

University Hospital Basel Patients: Patients with acute HF not requiring ICU admission

Patients admitted to the emergency department with acute HF will be randomized to:

• Early goal-directed preload and afterload decrement using a fixed therapy schedule including sublingual and transdermal nitrates, and hydralazine, followed by rapid up-titration of ACE-inhibitors or AT-receptor blockers to achieve maximal vasodilatation with a target systolic blood pressure of 90-110 mmHg. All other elements of treatment will be according to the current guidelines of the European Society of Cardiology (ESC)

• Standard treatment of acute HF according to the current guidelines of the ESC.

Clinical Significance: Despite the clinical and economical importance of acute HF, the optimal treatment of acute HF is ill-defined. We strongly believe that our novel therapeutic strategy will significantly reduce morbidity, length of hospitalisation, and possibly mortality of affected patients. This would represent a first major step for an evidence-based management of this common condition. Documenting medical and economic benefit of a simple, safe, and inexpensive medical therapy in a randomised controlled clinical trial would provide evidence-based care for the majority of patients presenting with acute HF worldwide. All drugs applied in our strategy are off-patent and therefore relatively low-cost. Successful implication of our treatment algorithm has the potential to significantly reduce treatment costs.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 781
• Est. completion date: February 21, 2019
• Est. primary completion date: August 24, 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Acute HF expressed by acute dyspnea New York Heart Association (NYHA) class III or IV, and a BNP-level = 500 pg/ml. The diagnosis of acute HF is additionally based on typical symptoms and clinical findings, supported by appropriate investigations such as ECG, chest X-ray, and Doppler-echocardiography as recommended by current ESC guidelines on the diagnosis and treatment of acute HF

Exclusion Criteria:

• Cardiopulmonary resuscitation < 7 days

• Cardiogenic shock, ST-elevation myocardial infarction, or other clinical conditions that require immediate ICU admission or urgent PTCA

• Systolic blood pressure lower than 100 mmHg at presentation

• Primary rhythmogenic cause of acute decompensation (ventricular tachycardia, reentry tachycardia, atrial fibrillation or atrial flutter with a ventricular rate exceeding 140 beats per minute)

• NSTEMI as primary diagnosis

• Severe aortic stenosis

• Adult congenital heart disease as primary cause of acute HF

• Hypertrophic obstructive cardiomyopathy

• Chronic kidney disease with creatinin levels > 250 µmol/l

• Bilateral renal artery stenosis

• Severe sepsis or other causes of high output failure

• Cirrhosis of the liver CHILD class C

• Previous adverse reactions to nitrates

Related Conditions & MeSH terms

• Acute Heart Failure
• Heart Failure

Intervention

Drug:
• Goal-directed preload and afterload decrement
Early goal-directed preload and afterload decrement with a target systolic blood pressure (RR) of 90-110 mmHg for the entire hospitalization using sublingual nitrates (Nitroglycerin Streuli®) or nitrospray (Corangin Nitrospray®) transdermal nitrates (Nitroderm TTS 10®), ACE-inhibitors (Triatec®) and/or ARB (Atacand®).

Locations

Country	Name	City	State
Brazil	Hospital Sao Paolo	São Paulo
Bulgaria	5-th Multifunctional Hospital for Active Treatment	Sofia
Bulgaria	National Transport Hospital "Tsar Boris III"	Sofia
Bulgaria	University Hospital "Tsaritsa Joanna-ISUL"	Sofia
Germany	University Hospital Mainz	Mainz
Germany	Nuremberg Hospital	Nuremberg
Spain	Hospital Universitari Germans Trias i Pujol	Badalona
Spain	Hospital de la Santa Creu i Sant Pau	Barcelona
Switzerland	Kantonsspital Aarau	Aarau
Switzerland	University Hospital Basel	Basel	BS
Switzerland	Kantonsspital Luzern	Luzern
Switzerland	Kantonsspital St. Gallen	St. Gallen

Sponsors (1)

Lead Sponsor	Collaborator
University Hospital, Basel, Switzerland

Countries where clinical trial is conducted

Brazil,  Bulgaria,  Germany,  Spain,  Switzerland, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Death or re-hospitalization from HF	Death or re-hospitalization due to heart failure at 180 days	180 days
Secondary	All-cause mortality	All-cause mortality at 180 days	180 days
Secondary	HF re-hospitalization	Re-hospitalization due to heart failure at 180 days	180 days